William Blair analyst Ryan Daniels has maintained their bullish stance on TMDX stock, giving a Buy rating on July 21.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ryan Daniels has given his Buy rating due to a combination of factors including anticipated strong sales and earnings performance from TransMedics Group in the upcoming second quarter. His confidence is bolstered by the analysis of industry transplant volumes, particularly liver transplants, which constitute a significant portion of the company’s sales, as well as data on TransMedics’ flight volumes.
Despite the positive outlook for the second quarter, Daniels acknowledges potential challenges in the second half of the year due to typical seasonal patterns. Historically, transplant volumes, including liver, heart, and lung transplants, have shown a decline in the third quarter, likely attributed to summer vacations affecting transplant staff availability. This seasonal trend could lead management to adopt a more cautious approach in their guidance for the latter part of the year.
Daniels covers the Healthcare sector, focusing on stocks such as Addus Homecare, Evolent Health, and TransMedics Group. According to TipRanks, Daniels has an average return of 5.3% and a 42.54% success rate on recommended stocks.
In another report released on July 21, TD Cowen also maintained a Buy rating on the stock with a $170.00 price target.